Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2026)

Intellia Therapeutics (NTLA) has 3 years of Other Operating Expenses data on file, last reported at $904000.0 in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 57.46% year-over-year to $904000.0 in Q1 2026; TTM through Mar 2026 was -$2.1 million, a 94.19% increase from a year earlier, with the FY2025 full-year figure at -$899000.0, up 97.24% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $904000.0, down from $1.8 million in the prior quarter.
• Over the last five years, Other Operating Expenses for NTLA reached as high as $20.4 million in Q2 2024 and fell as low as -$62.0 million in Q4 2024.
• Historically, Other Operating Expenses has averaged -$3.6 million across 3 years, with a median of $1.8 million in 2025.
• On a YoY basis, Other Operating Expenses climbed as much as 102.83% in 2025 and fell as far as 212.24% in 2025.
• Year by year, Other Operating Expenses stood at -$62.0 million in 2024, then soared by 102.83% to $1.8 million in 2025, then sank by 48.46% to $904000.0 in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $904000.0 in Q1 2026, $1.8 million in Q4 2025, and -$3.4 million in Q3 2025.